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Abstract
Streptococcus pneumoniae infection is a leading cause of morbidity and mortality worldwide. One of the most severe complications of
invasive pneumococcal disease (IPD) is haemolytic uraemic syndrome (HUS). This study was undertaken to determine the risk factors
and role of pneumococcal neuraminidases in HUS in children with IPD. Eighteen cases of HUS and 54 patients with IPD without HUS
were identiﬁed. The controls were patients with culture-conﬁrmed IPD without HUS. Clinical and laboratory characteristics of the two
groups of patients were compared. Bacterial isolates from both groups were serotyped, sequence typed and examined for their carriage
of three neuraminidase genes. Necrotizing pneumonia and serotype 3 infection were signiﬁcantly associated with HUS in children with
IPD, suggesting that a severe pulmonary suppurating disease increase the risk of HUS. Serotype 14 was associated with necrotizing
pneumonia but not HUS. Children with HUS were more likely to require surgery and had a longer duration of hospitalization. The
study identiﬁed a signiﬁcantly higher carriage of a neuraminidase gene, nanC, in the causative pneumococcal isolates from patients with
HUS (89% versus 41%, p 0.001). The sensitivity and speciﬁcity of nanC to predict HUS were 89% and 59%, respectively. In conclusion,
necrotizing pneumonia, serotype 3 infection and neuraminidase gene nanC were associated with HUS in children with IPD. The result
suggests that NanC could provide an additive effect to NanA and NanB in the overall activity of pneumococcal neuraminidases to
expose Thomsen–Friedenreich antigen on various cells in patients with HUS.
Keywords: Haemolytic uraemic syndrome, invasive pneumococcal disease, necrotizing pneumonia, neuraminidase, Streptococcus pneumo-
niae, Thomsen–Friedenreich antigen
Original Submission: 28 November 2011; Revised Submision: 2 April 2012; Accepted: 7 April 2012
Editor: J.-L. Mainardi
Article published online: 27 April 2012
Clin Microbiol Infect 2013; 19: 480–486
10.1111/j.1469-0691.2012.03894.x
Corresponding author: C.-H. Chiu, Department of Paediatrics,
Chang Gung Children’s Hospital, 5 Fu-Hsin Street, Kweishan 333,
Taoyuan, Taiwan
E-mail: chchiu@adm.cgmh.org.tw
Introduction
Streptococcus pneumoniae can colonize in the nasopharynx of
children and subsequently cause diseases such as otitis
media, pneumonia, bacteraemia and meningitis [1,2]. During
inﬂuenza pandemics, pneumococcal pneumonia following
inﬂuenza infection increases the disease severity and leads to
death [3–7]. In the USA, S. pneumoniae was the leading path-
ogen found in the lung specimens of fatal cases of 2009 pan-
demic inﬂuenza A (H1N1) [8].
One of the most severe complications of invasive pneumo-
coccal infection is haemolytic uraemic syndrome (HUS),
which mainly occurs in children and is associated with haemo-
lytic anaemia, thrombocytopenia and acute renal failure [9–
11]. Although S. pneumoniae encodes many virulence factors,
only secreted neuraminidase A (NanA) was attributed to
HUS [6,11]. Inﬂuenza virus encodes the neuraminidase NA,
which is similar to S. pneumoniae NanA in substrate speciﬁcity
[12,13]. NanA cleaves N-acetylneuraminic acid (sialic acid)
residues on red blood cells, platelets and endothelial cells
leading to the exposure of the Thomsen–Friedenreich antigen
(TA) and allowing normally circulating anti-T antigen antibod-
ies to react with the exposed TA on cells [9,14]. Management
of HUS primarily includes intensive antimicrobial therapy,
dialysis and transfusion of washed red blood cells, platelets
and plasma [14,15]. Streptococcus pneumoniae-associated HUS
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
was ﬁrst described by Fischer et al. in 1971 and has since
been recognized as an emerging problem [11,16]. The mortal-
ity of patients with HUS was high in early studies [14,16]. In a
recent study from USA, of the 14 patients with pneumococ-
cal HUS, one (7%) died and three (21%) developed chronic
kidney disease [10]. Because of the substantial morbidity and
mortality, this investigation has been undertaken to analyse
the clinical characteristics and identify risk factors of HUS in
children with pneumococcal infection.
Materials and Methods
Patients
A case–control study was conducted using the clinical data
from Chang Gung Children’s Hospital. We deﬁned invasive
pneumococcal disease (IPD) by isolation of S. pneumoniae
from normally sterile sites such as blood, cerebrospinal ﬂuid,
or pleural ﬂuid. Patients were children <18 years old hospi-
talized with a diagnosis of HUS associated with an IPD
between January 2006 and December 2009. The HUS was
deﬁned using the CDC deﬁnition [17]. Coagulation studies
were examined at the time of HUS diagnosis. The presence
of normal ﬁbrinogen levels in the presence of diagnostic cri-
teria for HUS was used to rule out disseminated intravascu-
lar coagulopathy. All the children with HUS who were
enrolled were conﬁrmed for TA activation by the peanut
(Arachis hypogaea) lectin agglutination method [11]. From the
patients with IPD who were treated in Chang Gung Chil-
dren’s Hospital, three control patients were identiﬁed at ran-
dom for each patient with HUS, matched for year of
hospitalization. Controls had no evidence of acute renal fail-
ure or haemolytic anaemia.
The following clinical information was reviewed: demo-
graphic data, clinical characteristics, laboratory data, treat-
ment and outcome. Complicated pneumococcal pneumonia
includes necrotizing pneumonia and empyema. Necrotizing
pneumonia was deﬁned as multiple small lucencies or
pneumatocoeles on a chest radiograph and as cavities of
non-enhancement on a contrast-enhanced computerized
tomographic image. Empyema was deﬁned as the presence of
one major criterion or two minor criteria as described earlier
[18]. All cases with necrotizing pneumonia underwent a com-
puterized tomographic scan, which conﬁrmed the diagnosis.
All 18 HUS patients were surveyed for possible viral infec-
tions using previously described methods [19]. A positive
viral culture or direct ﬂuorescent antibody test was consid-
ered indicative of infection by that organism. The direct ﬂuo-
rescent antibody test and cultures were performed using
nasopharyngeal or oropharyngeal swabs. Furthermore, all
HUS patients received serological testing for Mycoplasma
pneumoniae infection by enzyme-linked immunosorbent assay
(Savyon Diagnostics Ltd, Ashdod, Israel). The diagnosis of
active infection with M. pneumoniae was based on an at least
four-fold rise in mycoplasma particle agglutinin titre in paired
sera or the presence of anti-mycoplasma IgM.
Serotyping and multilocus sequence typing
Eighteen pneumococcal isolates were recovered from blood
(n=16) and pleural effusion ﬂuid (n=2) of patients with HUS
and 54 from blood (n=39), pleural ﬂuid (n=14) and cerebro-
spinal ﬂuid (n=1) of patients with IPD. Serotyping and
sequence typing of the isolates was carried out as described
previously [20,21].
Detection of neuraminidase genes by PCR
There are three neuraminidases, NanA, NanB and NanC,
reported in pneumococci [22]. Neuraminidase genes were
detected in clinical isolates using primers as described earlier
[22]. Neuraminidase gene nanA (2941 base pairs (bp)) was
ampliﬁed by primers 5¢-AGATCTGGGTACCATGTCTTA
TTTCAGAAATCG-3¢ and 5¢-TGGTGCTCGAGTTGTTCTC
TCTTTTTCCCTA-3¢, nanB (2091 bp) by 5¢-AGATCTG
GGTACCATGAATAAAAGAGGTCTTTA-3¢ and 5¢-TGG
TGCTCGAGTTTTGTTAAATCATTAATTTC-3¢, and nanC
(2220 bp) by 5¢-AGATCTGGGTACCATGAAAAAAAATA
TTAAACA-3¢ and 5¢-TGGTGCTCGAGATTCTTTTTCAG
ATCTTCAA-3¢. Streptococcus pneumoniae strain CGSP14, a
serotype 14 clinical isolate derived from a child with HUS,
was used as a control [23].
Statistical methods
Statistical analysis was performed by using SPSS software ver-
sion 17.0 (SPSS, Chicago, IL, USA). The signiﬁcance was
determined using chi-square test or Mann–Whitney rank
sum for multivariant data and a p <0.05 was considered sig-
niﬁcant.
Results
Clinical characteristics of pneumococcal HUS
There were 18 children with culture-conﬁrmed IPD who
met the case deﬁnition of HUS in the study period. All of
these had TA activation. The non-HUS control group
included two subgroups: 42 patients with IPD without necro-
tizing pneumonia, including empyema in six, pneumonia with
bacteraemia in 34, and meningitis in two; and 12 patients
with necrotizing pneumonia. Clinical and laboratory charac-
teristics of pneumococcal HUS are shown in Tables 1 and 2.
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Patients with HUS were older compared with the 54
patients in the control group. Seventeen patients in the HUS
group required dialysis of various durations (mean:
8.2 ± 11.0 days). Almost all (17; 94%) had necrotizing pneu-
monia, compared with 22% (12/54) in the non-HUS control
group (p 0.001). All patients with HUS, including one with
only empyema, required chest tube drainage. Sixteen (89%)
patients received surgery, either lobectomy or pleural
debridement by video-assisted thoracoscopic surgery. The
duration of hospitalization was signiﬁcantly longer for
patients with HUS (p 0.04). There were no deaths in either
group.
In Taiwan, the heptavalent pneumococcal conjugate vac-
cine (PCV7) was introduced in October 2005. Only 15.9% of
children <5 years of age received one or more doses of the
vaccine by 2007 [24,25]. Given a low penetration rate, the
most predominant serotype to cause IPD remained the vac-
cine serotype 14 [24,25]. The only difference between the
HUS and non-HUS groups was serotype 3, which caused
necrotizing pneumonia in ﬁve of the 18 HUS patients but in
TABLE 1. Clinical and laboratory characteristics of patients with haemolytic uraemic syndrome (HUS), invasive pneumococcal
disease (IPD) excluding necrotizing pneumonia, and necrotizing pneumonia
Characteristics
HUS
n = 18
IPD without
necrotizing
pneumonia
n = 42
Necrotizing
pneumonia
n = 12 p value Odds ratio
Age (months); mean ± SD
(95% CI)
63.14 ± 34.0 (24–120) 49.83 ± 50.0 (5–120) 55.00 ± 28.7 (12–96) 0.004a, <0.001b
<0.001c, 0.070d
Gender (% female) 77 45 58
Lowest haemoglobin (g/dL) ;
mean ± SD (95% CI)
8.1 ± 1.6 (4.5–10.2) 11.1 ± 2.1 (8.5–13.4) 10.9 ± 1.37 (8.2–12.2) <0.001a, 0.724b
<0.001c, <0.001d
0.657a, 1.067b
0.667c, 0.789d
Lowest platelet count; mean ± SD
(95% CI)
67 769 ± 62 313
(7000–168 000)
304 478 ± 136 268
(47 000–562 000)
320 666 ± 253 712
(34 000–759 000)
<0.001a, 0.909b
0.012c, <0.001d
12.500a, 2.375b
4.500c, 10.688d
Highest blood urea nitrogen;
mean ± SD (95% CI)
61 ± 34.3 (20–152) 15.1 ± 17.8 (5–77) 13.7 ± 7.0 (9–25) <0.001a, 0.815b
0.001c, 0.011d
10.389a, 1.143b
21.000c, 4.000d
Highest creatinine; mean ± SD
(95% CI)
2.1 ± 1.4 (0.6–4.4) 0.4 ± 0.1 (0.3–0.6) 0.6 ± 0.3 (0.3–1) <0.001a, 0.217b
0.001c, 0.002d
1.050a, 1.190b
1.350c, 1.607d
Dialysis (days) 8.2 ± 11.0 (0–35) 0 0
Chest tube 18/18 (100%) 5/42 (12%) 10/12 (83%) 0.011a, <0.001b
0.193c, <0.001d
Operation 16/18 (89%) 4/42 (10%) 10/12 (83%) 0.220a, 0.002b
0.193c, 0.046d
Duration of hospital stay (days) ;
mean ± SD (95% CI)
31.4 ± 15.1 (11–65) 16.6 ± 23.4 (0–136) 26.2 ± 9.0 (16–39) 0.044a, 0.147b
0.683c, 0.001d
Neuraminidase C 16/18 (89%) 16/42 (38%) 6/12 (50%) 0.002a, 0.459b
0.051c, 0.001d
SD, standard deviation.
aHUS compared with non-HUS (IPD including necrotizing pneumonia).
bIPD excluding necrotizing pneumonia compared with necrotizing pneumonia.
cHUS compared with necrotizing pneumonia.
dHUS compared with IPD excluding necrotizing pneumonia.
TABLE 2. Serotype and sequence type distribution among Streptococcus pneumoniae isolates causing haemolytic uraemic syn-
drome (HUS), invasive pneumococcal disease (IPD) excluding necrotizing pneumonia, and necrotizing pneumonia
Serotypes
HUS
n = 18
IPD without necrotizing pneumonia
n = 42
Necrotizing pneumonia
n = 12 p value
14 9 (50%):
ST46 (5), ST2652 (1), ST1508 (1),
ST876 (1), ST95 (1)
11 (26%):
ST876 (4), ST46 (3), ST13 (3), ST2652 (1)
9 (75%):
ST876 (5), ST46 (2),
ST13 (1), ST81 (1)
0.441a, 0.043b
0.087c, 0.073d
3 5 (27%):
ST180 (5)
3 (7%):
ST180 (2), ST1569 (1)
1 (8%):
ST180 (1)
0.026a, 0.828b
0.228c, 0.031d
19F 2 (11%):
ST236 (2)
7 (17%):
ST2920 (3), ST236 (2), ST320 (1), ST3182 (1)
0 0.817a, 0.146b
0.252c, 0.581d
19A 1 (6%):
ST320 (1)
5 (12%):
ST276 (2), ST320 (2), ST2920 (1)
2 (17%):
ST320 (2)
0.364a, 0.605b
0.279c, 0.437d
6B 1 (6%):
ST46 (1)
9 (21%):
ST95 (3), ST90 (3), ST76 (2), ST3184 (1)
0 0.229a, 0.092b
0.426c, 0.131d
23F 0 7 (17%):
ST81 (4), ST242 (2), ST83 (1)
0
NS, not signiﬁcant.
aHUS compared with non-HUS (IPD including necrotizing pneumonia).
bIPD excluding necrotizing pneumonia compared with necrotizing pneumonia.
cHUS compared with necrotizing pneumonia.
dHUS compared with IPD excluding necrotizing pneumonia.
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only four of the 54 controls (p 0.026). The difference
remained when comparing HUS with IPD excluding necrotiz-
ing pneumonia (p 0.031). The difference in the rate of sero-
type 3 infection between groups of HUS and necrotizing
pneumonia (no HUS) was not signiﬁcant (p 0.228). The
responsible serotypes for necrotizing pneumonia in 12 con-
trol patients were serotypes 14 (nine isolates), 19A (two iso-
lates) and 3 (one isolate). Serotype 14 is a serotype
associated with necrotizing pneumonia (p 0.043) but not
HUS. Compared with the patients with IPD, patients with
necrotizing pneumonia were older and usually required surgi-
cal treatment (Table 1). Sequence types of the isolates are
shown in Table 2. Serotypes 3, 14 and 19A revealed a lim-
ited number of established clonal complexes. There was no
signiﬁcant difference in terms of sequence type distribution
in clinical isolates derived from the two groups of patients.
Virological surveys showed that among the 18 patients with
HUS, three had inﬂuenza A infection (all H1N1, one from the
2006–07 season and two from the 2007–08 season), one
patient each had culture-conﬁrmed infection caused by adenovi-
rus and enterovirus, parainﬂuenza virus and metapneumovirus.
This result was consistent with the notion that viral infections
predispose to increased risks of S. pneumoniae infections.
Detection of nanA, nanB and nanC in pneumococcal isolates
NanA and NanB have been studied and considered to be vir-
ulence factors of S. pneumoniae [26]. The role of NanC
remains poorly understood [22,27,28]. The nanC gene was
found in the genome of a serotype 14 isolate that was
derived from a child with HUS [23]. We therefore examined
the distribution of the three neuraminidase genes in pneumo-
coccal isolates from children with HUS and from control
children. Streptococcus pneumoniae intrinsically carried nanA
and nanB, as 100% of isolates from both groups had the two
genes; however, in contrast to the 16 (89%) HUS isolates
that harboured nanC, only 22 (41%) isolates from the 54
controls carried the gene (p 0.002) (Fig. 1a). As shown in
Table 2, such a difference was also found when comparing
HUS isolates with isolates from IPD excluding necrotizing
pneumonia (p 0.001). The difference was not signiﬁcant
(p 0.051) when HUS isolates were compared with isolates
from necrotizing pneumonia patients. Given the fact that
almost all patients with HUS had necrotizing pneumonia, the
result suggests that NanC could be a virulence factor for
necrotizing pneumonia as well as for HUS.
Serotype distribution and rate of nanC carriage in S. pneu-
moniae isolated from patients with or without HUS are
shown in Fig 1(b). The results suggest that the nanC gene is
one, but not the sole, microbial factor for HUS caused by
S. pneumoniae serotypes.
Discussion
Complicated pneumonia, necrotizing pneumonia in particular,
and serotype 3 infection were predictors for development of
HUS in children with IPD. The high incidence of necrotizing
pneumonia shown in this and previous studies suggests that
a heavy bacterial load and severe suppurating disease may
increase the risk of HUS, especially in the setting of a pulmo-
nary infection [10,29]. Serotype 14, ST46 in particular, has
been reported to be the aetiology responsible for the
increase of complicated pneumonia in Taiwan since the late
1990s [25]. The epidemiological feature has not vanished,
probably because of the suboptimal use of PCV7 [25,30]. On
the other hand, serotype 3 is a virulent serotype that usually
causes complicated pneumonia in adults as well as in children
[31]. In the USA, ST180 represents the most common
(b)
(a)
FIG. 1. Detection of nanA, nanB and nanC gene among Streptococcus
pneumoniae isolates derived from patients with haemolytic uraemic
syndrome (HUS) and controls. (a) Streptococcus pneumoniae intrinsi-
cally carried nanA and nanB; however, relative to 16 (89%) of the
HUS isolates that harboured nanC, only 22 (41%) isolates from the
54 controls carried the gene (*p 0.002). (b) Percentage of nanC gene
carriage in serotypes of S. pneumoniae isolates.
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sequence type of serotype 3 both before and after the intro-
duction of PCV7 [22,32]. In Utah, HUS occurred most fre-
quently following pneumonia and empyema because of
serotypes 1, 3 and 7F [33]. Our ﬁnding supports the notion
that pneumococcal serotypes with a high predilection to
cause complicated pneumonia are major aetiologies for HUS.
The study identiﬁed nanC as a signiﬁcant marker of
S. pneumoniae for pneumococcal HUS. In the setting of IPD,
The sensitivity and speciﬁcity of nanC to predict HUS are
89% and 59%, respectively. Similar results were reported in
an earlier study showing that detectable neuraminidase activ-
ity by peanut lectin assay was sensitive (100%) but not that
speciﬁc (48%) for HUS [24]. Pettigrew et al. [22] from USA
reported that among the invasive isolates nanB and nanC
were present in 95% and 58% of the isolates, respectively;
however, in non-invasive isolates nanB and nanC were pres-
ent in 96% and 47% of the isolates, respectively. Recently,
Imai et al. [34] from Japan reported that among the 156
pneumococcal isolates recovered from adult patients with
community-acquired pneumonia nanC was present in 35.9%
of the isolates. Several studies reported that neuraminidase
exposes TA on cells in patients with HUS [9,16,24,35]. The
terms ‘circulating neuraminidase’ or ‘extracellular neuramini-
dase’ are being widely used in these reports to describe
neuraminidase-mediated exposure of TA [9,16,33]. However,
none of these studies examined the role of NanC. In an in vi-
tro study, we have successfully cloned and expressed NanC
and conﬁrmed that in addition to NanA and NanB, NanC is
functional and can exert neuraminidase activity by exposing
TA on red blood cells and respiratory tract epithelial cells
(C.-H. Chiu, unpublished data). A recent study showed that
NanA but not NanB was necessary for TA exposure on red
blood cells in mice [6]. Nevertheless, based on our results,
we speculate that NanC might contribute to the risk of
developing HUS in an additive manner in the presence of
NanA and NanB by increasing the overall activity of pneumo-
coccal neuraminidases to expose TA on cells, and so was
associated with the occurrence of HUS following pneumo-
coccal infection.
In humans, antibody titres to TA can be detected in most
infants by 6 months of age [35]. More TA exposure and
greater possibility of TA and anti-TA immune complex for-
mation could lead to subsequent lysis of the cells in young
children with IPD [9,36]. During pneumococcal infection,
some cytosolic proteins such as pneumolysin are released
when pneumococci undergo spontaneous autolysis [37]. An
earlier study found that penicillin treatment during lung infec-
tion of mice enhanced TA exposure on circulating red blood
cells [6]. It is likely that intracellular NanB and NanC
released by autolysis of pneumococci could reach the circula-
tory system and the overall activity of the three pneumococ-
cal neuraminidases would predispose children with severe
pulmonary infection to HUS.
A lethal synergy exists between inﬂuenza virus and
S. pneumoniae, the most common cause of community-
acquired pneumonia in children. Some clinical studies showed
that use of oseltamivir in the early stage of inﬂuenza infec-
tion prevents subsequent bacterial infection [38,39]. As
shown in this study, one-third of the patients with S. pneumo-
niae-associated HUS had culture-conﬁrmed concomitant viral
infection, including inﬂuenza. The result mandates future clin-
ical trials to evaluate the potential of neuraminidase inhibi-
tors to prevent pneumococcal infections and subsequent
HUS following inﬂuenza infection.
Even in the PCV7 era, necrotizing pneumonia or empyema
caused by S. pneumoniae remains a growing problem world-
wide. The study found that necrotizing pneumonia requiring
surgery as well as serotype 3 infection was associated with
HUS in children with IPD. In the USA and in Taiwan, infection
with S. pneumoniae serotype 3 (mainly ST180) was a signiﬁcant
contributor to necrotizing pneumonia [24,25,32,33]. In Tai-
wan, serotype 14 was another common serotype that caused
necrotizing pneumonia [24,25]. However, there is no exclu-
siveness; some other serotypes including 6B, 14, 19F, 23F and
19A, in spite of a lower frequency, may also cause necrotizing
pneumonia and even HUS. As there are multiple variables, the
correlation of the serotype and sequence type proﬁles with
necrotizing pneumonia and HUS can be inﬂuenced by other
factors such as host factors and geographic difference. Never-
theless, we demonstrated in this study the predominance of
nanC-bearing serotypes in necrotizing pneumonia and HUS, in
comparison with IPD without necrotizing pneumonia and
HUS. Immunization with conjugate vaccines that cover more
serotypes including those for complicated pneumonia should
be helpful to reduce the occurrence of pneumococcal HUS.
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